BioAtla reports Phase 1 data for BA3071: confirmed responses in solid tumors, safe profile, Phase 2 initiated

BioAtla, Inc.

Phase 1 dose-escalation of BA3071 (CAB-CTLA-4) in 18 PD-1-failure patients: 2 confirmed responses (1 CR stage IV cervical, 1 PR stage IV gastro-esophageal), 9 stable disease.
No grade 4 treatment-emergent adverse events; two grade 3 immune-related AEs. Maximum tolerated dose not reached; DLT at 700 mg.
Durable disease control: uveal melanoma (>12 cycles), cutaneous melanoma (>14, >17 cycles), SCLC (>22 cycles).
Phase 2 monotherapy and in combination with PD-1 inhibitor is now underway.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.